Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Inhibitors for Up to 10 Years

REFERENCES

1. 1.↵
   1. Landewé R,
   2. Dougados M,
   3. Mielants H,
   4. van der Tempel H,
   5. van der Heijde D

   . Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis 2009;68:863–7.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Aletaha D,
   2. Ward MM

   . Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials. Ann Rheum Dis 2006;65:227–33.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Creemers MC,
   2. Franssen MJ,
   3. van’t Hof MA,
   4. Gribnau FW,
   5. van de Putte LB,
   6. van Riel PL

   . Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005;64:127–9.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Wanders A,
   2. Landewé R,
   3. Dougados M,
   4. Mielants H,
   5. van der Linden S,
   6. van der Heijde D

   . Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation? Ann Rheum Dis 2005;64:988–94.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Machado P,
   2. Landewé R,
   3. Braun J,
   4. Hermann KG,
   5. Baker D,
   6. van der Heijde D

   . Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis 2010;69:1465–70.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. van der Heijde D,
   2. Landewé R,
   3. Baraliakos X,
   4. Houben H,
   5. van Tubergen A,
   6. Williamson P,
   7. et al;
   8. Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group

   . Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008;58:3063–70.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. van der Heijde D,
   2. Landewé R,
   3. Einstein S,
   4. Ory P,
   5. Vosse D,
   6. Ni L,
   7. et al.

   Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008;58:1324–31.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. van der Heijde D,
   2. Salonen D,
   3. Weissman BN,
   4. Landewé R,
   5. Maksymowych WP,
   6. Kupper H,
   7. et al;
   8. Canadian (M03-606) study group;
   9. ATLAS study group

   . Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009;11:R127.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Braun J,
   2. Baraliakos X,
   3. Hermann KG,
   4. Deodhar A,
   5. van der Heijde D,
   6. Inman R,
   7. et al.

   The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. Ann Rheum Dis 2014;73:1107–13.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Baraliakos X,
    2. Haibel H,
    3. Listing J,
    4. Sieper J,
    5. Braun J

    . Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis 2014;73:710–5.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Haroon N,
    2. Inman RD,
    3. Learch TJ,
    4. Weisman MH,
    5. Lee M,
    6. Rahbar MH,
    7. et al.

    The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis Arthritis Rheum 2013;65:2645–54.

    OpenUrl
12. 12.↵
    1. Sieper J,
    2. Appel H,
    3. Braun J,
    4. Rudwaleit M

    . Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Arthritis Rheum 2008;58:649–56.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Maksymowych WP,
    2. Elewaut D,
    3. Schett G

    . Motion for debate: the development of ankylosis in ankylosing spondylitis is largely dependent on inflammation. Arthritis Rheum 2012;64:1713–9.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Maksymowych WP,
    2. Morency N,
    3. Conner-Spady B,
    4. Lambert RG

    . Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification. Ann Rheum Dis 2013;72:23–8.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Braun J,
    2. Brandt J,
    3. Listing J,
    4. Zink A,
    5. Alten R,
    6. Golder W,
    7. et al.

    Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187–93.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Brandt J,
    2. Khariouzov A,
    3. Listing J,
    4. Haibel H,
    5. Sorensen H,
    6. Grassnickel L,
    7. et al.

    Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667–75.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Baraliakos X,
    2. Listing J,
    3. Fritz C,
    4. Haibel H,
    5. Alten R,
    6. Burmester GR,
    7. et al.

    Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years—early clinical response predicts long-term outcome. Rheumatology 2011;50:1690–9.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Baraliakos X,
    2. Haibel H,
    3. Fritz C,
    4. Listing J,
    5. Heldmann F,
    6. Braun J,
    7. et al.

    Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. Arthritis Res Ther 2013;15:R67.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Garrett S,
    2. Jenkinson T,
    3. Kennedy LG,
    4. Whitelock H,
    5. Gaisford P,
    6. Calin A

    . A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286–91.

    OpenUrlPubMed
20. 20.↵
    1. Calin A,
    2. Garrett S,
    3. Whitelock H,
    4. Kennedy LG,
    5. O’Hea J,
    6. Mallorie P,
    7. et al.

    A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281–5.

    OpenUrlPubMed
21. 21.↵
    1. Jenkinson TR,
    2. Mallorie PA,
    3. Whitelock HC,
    4. Kennedy LG,
    5. Garrett SL,
    6. Calin A

    . Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994;21:1694–8.

    OpenUrlPubMed
22. 22.↵
    1. Maas F,
    2. Spoorenberg A,
    3. Brouwer E,
    4. Bos R,
    5. Efde M,
    6. Chaudhry RN,
    7. et al.

    Spinal radiographic progression in patients with ankylosing spondylitis treated with TNF-α blocking therapy: a prospective longitudinal observational cohort study. PLoS One 2015;10:e0122693.

    OpenUrl
23. 23.↵
    1. Smolen JS,
    2. Aletaha D,
    3. Grisar JC,
    4. Stamm TA,
    5. Sharp JT

    . Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. Ann Rheum Dis 2010;69:1058–64.

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    1. van Tubergen A,
    2. Ramiro S,
    3. van der Heijde D,
    4. Dougados M,
    5. Mielants H,
    6. Landewé R

    . Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: a longitudinal study. Ann Rheum Dis 2012;71:518–23.

    OpenUrlAbstract/FREE Full Text
25. 25.↵
    1. Poddubnyy D,
    2. Haibel H,
    3. Listing J,
    4. Märker-Hermann E,
    5. Zeidler H,
    6. Braun J,
    7. et al.

    Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum 2012;64:1388–98.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Wanders A,
    2. Heijde Dv,
    3. Landewé R,
    4. Béhier JM,
    5. Calin A,
    6. Olivieri I,
    7. et al.

    Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005;52:1756–65.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. Poddubnyy D,
    2. Rudwaleit M,
    3. Haibel H,
    4. Listing J,
    5. Märker-Hermann E,
    6. Zeidler H,
    7. et al.

    Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 2012;71:1616–22.

    OpenUrlAbstract/FREE Full Text
28. 28.↵
    1. Kroon F,
    2. Landewé R,
    3. Dougados M,
    4. van der Heijde D

    . Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 2012;71:1623–9.

    OpenUrlAbstract/FREE Full Text